Taxotere® (docetaxel) Significantly Improves The Survival Of Patients With Advanced Prostate Cancer

... Sanofi-aventis today announced, at the ASCO Prostate Cancer Symposium, long term survival results of the large TAX 327 Phase III clinical trial. The overall survival benefit for the patients with metastatic hormone refractory prostate cancer (mHRPC), receiving 3-weekly 75mg/m2 Taxotere® (docetaxel)-prednisone regimen compared to mitoxantrone-prednisone gives a median survival 19. [click link for full article] ...